A Randomized Phase II Trial of Nal-IRI and 5-Fluorouracil Compared to 5-Fluorouracil in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies

Trial Profile

A Randomized Phase II Trial of Nal-IRI and 5-Fluorouracil Compared to 5-Fluorouracil in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Irinotecan (Primary) ; Fluorouracil; Folinic acid
  • Indications Cholangiocarcinoma; Gallbladder cancer
  • Focus Therapeutic Use
  • Acronyms NALIRICC
  • Most Recent Events

    • 16 Aug 2017 Planned initiation date changed from 1 Jul 2017 to 1 Sep 2017.
    • 15 Jun 2017 Planned End Date changed from 1 Apr 2021 to 1 Jul 2021.
    • 15 Jun 2017 Planned primary completion date changed from 1 Nov 2020 to 1 Jan 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top